Green et al., 1988 - Google Patents
Copper (II) bis (thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PETGreen et al., 1988
View PDF- Document ID
- 7393890387782207482
- Author
- Green M
- Klippenstein D
- Tennison J
- Publication year
- Publication venue
- Journal of nuclear medicine
External Links
Snippet
Copper(II) Bis(thiosemicarbazone) Complexes as Potential Tracers for Evaluation of Cerebral
and Myocardial Blood Flow with PET Page 1 he zinc-62/copper-62 (62Zn/@Cu) radionucide
generator (1—5)is a possible source of radiopharmaceu ticals for diagnostic imaging by positron …
- JPVYNHNXODAKFH-UHFFFAOYSA-N cu2+ data:image/svg+xml;base64,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 data:image/svg+xml;base64,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 [Cu+2] 0 title abstract description 12
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0476—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0497—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Green et al. | Copper (II) bis (thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET | |
| Boros et al. | Radioactive transition metals for imaging and therapy | |
| Jurisson et al. | Coordination compounds in nuclear medicine | |
| John et al. | Structure-activity relationships for metal-labeled blood flow tracers: comparison of keto aldehyde bis (thiosemicarbazonato) copper (II) derivatives | |
| Liu | The role of coordination chemistry in the development of target-specific radiopharmaceuticals | |
| Jones et al. | Biological studies of a new class of technetium complexes: the hexakis (alkylisonitrile) technetium (I) cations | |
| Mathias et al. | Evaluation of a potential generator-produced PET tracer for cerebral perfusion imaging: single-pass cerebral extraction measurements and imaging with radiolabeled Cu-PTSM | |
| Liu et al. | 99m Tc-centered one-pot synthesis for preparation of 99m Tc radiotracers | |
| Alberto et al. | Potential of the"[M (CO) 3]+"(M= Re, Tc) moiety for the labeling of biomolecules | |
| US20080267868A1 (en) | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | |
| JP3385048B2 (en) | Rhenium and technetium complexes containing hypoxia-localized residues | |
| Yang et al. | Formulation of 68Ga BAPEN kit for myocardial positron emission tomography imaging and biodistribution study | |
| Wharton et al. | H4picoopa─ Robust Chelate for 225Ac/111In Theranostics | |
| Baldas et al. | Effect of the Tc-nitrido group on the behaviour of 99mTc-radiopharmaceuticals | |
| Berning et al. | 198Au-labeled hydroxymethyl phosphines as models for potential therapeutic pharmaceuticals | |
| RU2568888C1 (en) | METHOD AND FORMULATION FOR PRODUCING 99m TC LABELLED 5-THIO-D-GLUCOSE AGENT FOR RADIONUCLIDE DIAGNOSIS | |
| RU2644744C1 (en) | Composition and method for production of 99m tc labelled 5-thio-d-glucose agent for radionuclide diagnosis | |
| Saha et al. | Radiopharmaceuticals and methods of radiolabeling | |
| Tisato et al. | Contribution of electrospray mass spectrometry for the characterization, design, and development of nitrido technetium and rhenium heterocomplexes as potential radiopharmaceuticals | |
| Zhang et al. | Synthesis and biodistribution of a new 99mTc nitrido complex for cerebral imaging | |
| Akerman et al. | Biodistribution (as determined by the radiolabelled equivalent) of a gold (III) bis (pyrrolide‐imine) Schiff base complex: a potential chemotherapeutic | |
| Zhang et al. | Synthesis of a bis-(N-sec-butyl-dithiocarbamato)-nitrido-99mTc complex: a potential new radiopharmaceutical for brain perfusion studies | |
| Wharton et al. | H3TPAN-Triazole-Bn-NH2: Tripicolinate Clicked-Bifunctional Chelate for [225Ac]/[111In] Theranostics | |
| Horiuchi et al. | The development of 99mTc-analog of Cu-DTS as an agent for imaging hypoxia | |
| Pervez et al. | 188 Rhenium-EDTMP: A potential therapeutic bone agent |